AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral body BMD
Number of subjects: 152
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Width-adjusted vertebral body BMD
Number of subjects: 152
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-vertebral body BMD
Number of subjects: 152
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Width-adjusted mid-vertebral body BMD
Number of subjects: 152
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck BMD
Number of subjects: 152
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanter BMD
Number of subjects: 152
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward's triangle BMD
Number of subjects: 152
Study 9116392 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body BMD
Number of subjects: 152
Study 1670725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 188
Study 1670725 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell vaccine
Number of subjects: 188
Study 6365873 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (250 mg 6 hourly iv)
Number of subjects: 186
Study 6365873 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1000 mg 6 hourly iv)
Number of subjects: 186
Study 30877239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low endothelial shear stress (ESS)
Number of subjects: 68
Study 30877239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ESS
Number of subjects: 68
Study 30877239 — intervention group
Group type: EXPERIMENTAL
Intervention: Standalone IVUS‐VH
Number of subjects: 68
Study 30458850 — intervention group
Group type: EXPERIMENTAL
Intervention: pre-CBT digital psychoeducation intervention
Number of subjects: 80
Study 30458850 — intervention group
Group type: COMPARATOR
Intervention: NHS choices website for CBT
Number of subjects: 80
Study 26454322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous haemocoagulase
Number of subjects: 46
Study 26454322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 22713145 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 200
Study 22713145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 200
Study 22713145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 200
Study 22713145 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 200
Study 22713145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 20381871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 392
Study 20381871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 392
Study 20381871 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 392
Study 18551110 — intervention group
Group type: EXPERIMENTAL
Intervention: Food temptation
Number of subjects: 97
Study 18551110 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 97
Study 15860476 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention consisting of six sessions and maintenance phase with one home and three brief telephone sessions
Number of subjects: 127
Study 15860476 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 127
Study 15860476 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 127
Study 12432174 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/Ex (Carbohydrate during exercise)
Number of subjects: 13
Study 12432174 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/NoEx (Carbohydrate without exercise)
Number of subjects: 13
Study 12432174 — intervention group
Group type: COMPARATOR
Intervention: NoCHO/Ex (Non-caloric placebo during exercise)
Number of subjects: 13
Study 12432174 — intervention group
Group type: COMPARATOR
Intervention: NoCHO/NoEx (Non-caloric placebo without exercise)
Number of subjects: 13
Study 10597756 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4698
Study 8558671 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml. 1% lidocaine
Number of subjects: 64
Study 8558671 — intervention group
Group type: COMPARATOR
Intervention: 5 ml. saline (0.9% sodium chloride)
Number of subjects: 64
Study 1678700 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg kg‐1)
Number of subjects: 50
Study 1678700 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg kg‐1)
Number of subjects: 50
Study 6389815 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin given by mouth in divided dosage
Number of subjects: 0
Study 6389815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 31617926 — intervention group
Group type: EXPERIMENTAL
Intervention: Active interventions (physical exercise, nutritional enhancement, cognitive training, combined treatment)
Number of subjects: 92
Study 31617926 — intervention group
Group type: EXPERIMENTAL
Intervention: Active interventions
Number of subjects: 92
Study 31617926 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 92
Study 29162334 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐Tac
Number of subjects: 50
Study 29162334 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 50
Study 26654880 — intervention group
Group type: EXPERIMENTAL
Intervention: dALAN exposure (5 lux)
Number of subjects: 23
Study 24354913 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic agency assigned to HPV (e.g., 'HPV preys on millions of people')
Number of subjects: 361
Study 24354913 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic agency assigned to vaccination (e.g., 'Vaccination guards people')
Number of subjects: 361
Study 24354913 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic agency assigned to HPV and vaccination
Number of subjects: 361
Study 22405597 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/day) for 2 years
Number of subjects: 28
Study 22405597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22405597 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with Kallmann syndrome
Number of subjects: 28
Study 20670438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracarpal injections of 1 ml triamcinolonacetonide 10 mg/ml (TCA)
Number of subjects: 69
Study 20670438 — intervention group
Group type: COMPARATOR
Intervention: 1 ml NaCl (placebo)
Number of subjects: 69
Study 17379125 — intervention group
Group type: COMPARATOR
Intervention: Traditional tidal volume ventilation (V(T), 10 mL/kg)
Number of subjects: 16
Study 17379125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (V(T), 6 mL/kg)
Number of subjects: 16
Study 17378787 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI-propofol and intravenously administered ketamine (n=9)
Number of subjects: 17
Study 17378787 — intervention group
Group type: COMPARATOR
Intervention: TCI-propofol alone (n=8)
Number of subjects: 17
Study 15077028 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction of tributaries from segment 5 or 8 (n=11)
Number of subjects: 20
Study 15077028 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction of the middle hepatic vein (MHV) (n=9)
Number of subjects: 20
Study 15077028 — intervention group
Group type: COMPARATOR
Intervention: Standard grafts with only right-sided hepatic vein(s) (n=45)
Number of subjects: 20
Study 10861141 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 60
Study 10861141 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 60
Study 9116609 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. acyclovir 500 mg/m2 three times a day from 5 days before transplant to 30 days after transplant followed by oral acyclovir 800 mg four times a day for a further 6 months
Number of subjects: 0
Study 9116609 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. acyclovir followed by placebo
Number of subjects: 0
Study 9116609 — intervention group
Group type: COMPARATOR
Intervention: 400 mg oral acyclovir four times a day followed by placebo (control)
Number of subjects: 0
Study 8237870 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (2.7 mumol Se)
Number of subjects: 0
Study 8237870 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (2.9 mumol Se)
Number of subjects: 0
Study 8237870 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented women
Number of subjects: 0
Study 3921097 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy alone
Number of subjects: 4860
Study 3921097 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics alone
Number of subjects: 4860
Study 3921097 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy and antibiotics combined
Number of subjects: 4860
Study 3921097 — intervention group
Group type: COMPARATOR
Intervention: Nose drops and analgesics
Number of subjects: 4860
Study 1097603 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazine (+/‐)‐10‐3‐dimethylamino‐2‐methylpropyl)‐2‐valeroylphenothiazine, 40 mg daily
Number of subjects: 9
Study 1097603 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study 31232274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of nifedipine GITS 60 mg and candesartan 32 mg
Number of subjects: 48
Study 31232274 — intervention group
Group type: COMPARATOR
Intervention: Loose combination of nifedipine and candesartan
Number of subjects: 48
Study 30279197 — intervention group
Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT) - aspirin only
Number of subjects: 870
Study 30279197 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) for an additional six months
Number of subjects: 870
Study 27039300 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS4BG (text message-based diabetes self-management support) in addition to usual care
Number of subjects: 1000
Study 27039300 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1000
Study 24356620 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 500 µg q3w
Number of subjects: 1234
Study 24356620 — intervention group
Group type: COMPARATOR
Intervention: Control (no darbepoetin alfa)
Number of subjects: 1234
Study 22537073 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitisation and reprocessing (EMDR) - eye movements (EM)
Number of subjects: 0
Study 19942640 — intervention group
Group type: EXPERIMENTAL
Intervention: 520 mg cocoa flavanols (CF)
Number of subjects: 30
Study 19942640 — intervention group
Group type: EXPERIMENTAL
Intervention: 994 mg cocoa flavanols (CF)
Number of subjects: 30
Study 19942640 — intervention group
Group type: COMPARATOR
Intervention: Matched control
Number of subjects: 30
Study 17367490 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ISI calibration
Number of subjects: 27
Study 17367490 — intervention group
Group type: COMPARATOR
Intervention: Direct INR
Number of subjects: 27
Study 16135584 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mug misoprostol orally
Number of subjects: 317
Study 16135584 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration
Number of subjects: 317
Study 16135584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 317
Study 12045677 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic suppressive fluconazole therapy
Number of subjects: 518
Study 12045677 — intervention group
Group type: COMPARATOR
Intervention: Episodic fluconazole therapy
Number of subjects: 518
Study 10463841 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 0
Study 10463841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10463841 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE patients with severe disease
Number of subjects: 0
Study 8545290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (4 mg)
Number of subjects: 32
Study 8545290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2483786 — intervention group
Group type: EXPERIMENTAL
Intervention: Crilanomer
Number of subjects: 95
Study 2483786 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextranomer
Number of subjects: 95
Study 875139 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 92
Study 875139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31230938 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA + CTP strategy (Group A)
Number of subjects: 2000
Study 31230938 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group B)
Number of subjects: 2000
Study 29462094 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 94
Study 29462094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 26920966 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine matrix with human thrombin
Number of subjects: 60
Study 26920966 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical methods
Number of subjects: 60
Study 24468860 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical recanalization
Number of subjects: 25
Study 22676931 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine (1:100,000)
Number of subjects: 88
Study 22676931 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine without epinephrine
Number of subjects: 88
Study 21034891 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncovered SEMS
Number of subjects: 129
Study 21034891 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially covered SEMS
Number of subjects: 129
Study 17435402 — intervention group
Group type: EXPERIMENTAL
Intervention: Error Reporting Promoting Program (ERPP)
Number of subjects: 26
Study 17435402 — intervention group
Group type: COMPARATOR
Intervention: Ordinary error-reporting method (Control)
Number of subjects: 26
Study 16285195 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug treatment
Number of subjects: 30
Study 16285195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12811943 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 100
Study 12811943 — intervention group
Group type: COMPARATOR
Intervention: Internal Fixation (IF)
Number of subjects: 100
Study 12811943 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich liquid supplementation with anabolic steroid
Number of subjects: 100
Study 12811943 — intervention group
Group type: COMPARATOR
Intervention: Undisplaced fractures
Number of subjects: 100
Study 12811943 — intervention group
Group type: COMPARATOR
Intervention: Displaced fractures
Number of subjects: 100
Study 11040889 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient detoxification
Number of subjects: 0
Study 11040889 — intervention group
Group type: COMPARATOR
Intervention: Out-patient treatment
Number of subjects: 0
Study 11040889 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist inpatient setting
Number of subjects: 0
Study 11040889 — intervention group
Group type: COMPARATOR
Intervention: General psychiatry inpatient setting
Number of subjects: 0
Study 8713559 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal electrical stimulation (MES) for 1 to 2 months
Number of subjects: 73
Study 8713559 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal electrical stimulation (MES)
Number of subjects: 73
Study 8713559 — intervention group
Group type: COMPARATOR
Intervention: Anal plug (control group) for 1 month
Number of subjects: 73
Study 1992876 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 17
Study 1992876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6611964 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-methyl PGF2 alpha with indomethacin suppositories before and during PG induction
Number of subjects: 30
Study 6611964 — intervention group
Group type: COMPARATOR
Intervention: 15-methyl PGF2 alpha only
Number of subjects: 30
Study 31486297 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Regainers (WR) (n=36)
Number of subjects: 77
Study 31486297 — intervention group
Group type: COMPARATOR
Intervention: Weight Maintainers (WM) (n=41)
Number of subjects: 77
Study 29939879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hyperinflation group
Number of subjects: 2575
Study 29939879 — intervention group
Group type: COMPARATOR
Intervention: Normal VE curve group
Number of subjects: 2575
Study 29939879 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 2575
Study 26913636 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children (BMI ≥ 85th percentile)
Number of subjects: 5532
Study 26913636 — intervention group
Group type: COMPARATOR
Intervention: Nonoverweight children
Number of subjects: 5532
Study 26913636 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with metabolic abnormalities (younger group)
Number of subjects: 5532
Study 26913636 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with highest quartile of BMI
Number of subjects: 5532
Study 26913636 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with highest quartile of 2-hour glucose
Number of subjects: 5532
Study 26913636 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure and cholesterol
Number of subjects: 5532
Study 24911423 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavioral therapy (CBT) intervention for 8 weeks
Number of subjects: 80
Study 24911423 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 80
Study 22891799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HI)
Number of subjects: 22
Study 22891799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Training (LI)
Number of subjects: 22
Study 22891799 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 19711113 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment for 12 months
Number of subjects: 384
Study 16984937 — intervention group
Group type: EXPERIMENTAL
Intervention: SASP
Number of subjects: 23
Study 16984937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (Group B)
Number of subjects: 4441
Study 15762946 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (Group A)
Number of subjects: 4441
Study 15762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Less comprehensive intervention (Group C)
Number of subjects: 4441
Study 15762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Less comprehensive intervention (Group D)
Number of subjects: 4441
Study 12127707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (LOMX) 400 mg once daily
Number of subjects: 182
Study 12127707 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (CIPX) 500 mg twice daily
Number of subjects: 182
Study 9771414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid solution (1 ml/minute for 30 minutes)
Number of subjects: 28
Study 9771414 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein solution (4.18 J/ml)
Number of subjects: 28
Study 9771414 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable electrolyte solution containing polyethylene glycol
Number of subjects: 28
Study 9771414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride solution
Number of subjects: 28
Study 7934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (pravastatin, nicotinic acid, cholestyramine, and gemfibrozil)
Number of subjects: 79
Study 7934538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 7934538 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 79
Study 3282033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5‐FU) 15 mg/kg/wk
Number of subjects: 141
Study 3282033 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (5‐FU) plus cisplatin (60 mg/m2 every 3 weeks)
Number of subjects: 141
Study 30807835 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-based adjunctive antimicrobial photodynamic therapy (aPDT) with perio green® 0.1 mg/ml and diode laser at 808 nm (100 mW at 2 kHz)
Number of subjects: 20
Study 30807835 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (control group)
Number of subjects: 20
Study 29972598 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential rumination
Number of subjects: 111
Study 29972598 — intervention group
Group type: COMPARATOR
Intervention: Analytical rumination
Number of subjects: 111
Study 29972598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 111
Study 27038632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prefrontal transcranial direct current stimulation (tDCS)
Number of subjects: 30
Study 27038632 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 24846054 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic ulcers
Number of subjects: 73
Study 24846054 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-ischemic ulcers
Number of subjects: 73
Study 24846054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic ulcers
Number of subjects: 73
Study 21861125 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARTp (small-incision access retroperitoneoscopic technique)
Number of subjects: 12
Study 21861125 — intervention group
Group type: COMPARATOR
Intervention: SRTp (standard retroperitoneoscopic technique)
Number of subjects: 12
Study 20849499 — intervention group
Group type: EXPERIMENTAL
Intervention: Clowns group (N = 25)
Number of subjects: 75
Study 20849499 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication group (N = 25)
Number of subjects: 75
Study 20849499 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 25)
Number of subjects: 75